share_log

424B3: Prospectus

424B3: Prospectus

424B3:募資說明書
美股sec公告 ·  06/27 08:17
Moomoo AI 已提取核心訊息
NeuroSense Therapeutics has filed a prospectus supplement with the Securities and Exchange Commission on June 27, 2024, updating and amending its previous prospectus dated April 8, 2024. The supplement pertains to the offering of 3,000,000 ordinary shares and warrants to purchase up to an additional 3,000,000 ordinary shares. The company's ordinary shares and warrants are traded on the Nasdaq under the symbols 'NRSN' and 'NRSNW', respectively. On June 26, 2024, the closing prices were $0.85 for ordinary shares and $0.18 for warrants. The supplement includes information from the company's Report on Form 6-K, which details amendments to certain warrants issued to an institutional investor. These amendments extend the termination date of warrants issued in June 2023 and April 2024 to October 12, 2029, and make adjustments to the 'Redemption Right' of the...Show More
NeuroSense Therapeutics has filed a prospectus supplement with the Securities and Exchange Commission on June 27, 2024, updating and amending its previous prospectus dated April 8, 2024. The supplement pertains to the offering of 3,000,000 ordinary shares and warrants to purchase up to an additional 3,000,000 ordinary shares. The company's ordinary shares and warrants are traded on the Nasdaq under the symbols 'NRSN' and 'NRSNW', respectively. On June 26, 2024, the closing prices were $0.85 for ordinary shares and $0.18 for warrants. The supplement includes information from the company's Report on Form 6-K, which details amendments to certain warrants issued to an institutional investor. These amendments extend the termination date of warrants issued in June 2023 and April 2024 to October 12, 2029, and make adjustments to the 'Redemption Right' of the 2023 Warrant. The company emphasizes the high degree of risk involved in investing in its securities and refers to the 'Risk Factors' section of the original prospectus for further details. The filing of this prospectus supplement is also incorporated by reference into the company's existing registration statements on Form S-8 and Form F-3.
NeuroSense Therapeutics於2024年6月27日向證券交易委員會提交了一份招股說明書,更新和修訂了其之前於2024年4月8日發佈的招股說明書。說明書涉及發行300萬普通股和權證,其可購買額外的300萬普通股。公司的普通股和權證分別在納斯達克上交易,代碼分別爲“NRSN”和“NRSNW”。2024年6月26日,普通股的收盤價爲0.85美元,權證的收盤價爲0.18美元。說明書包括來自公司提交的6-K表格的信息,該表格詳細說明了對某一名機構投資者發行的某些權證的修訂。這些修訂將於2023年6月和2024年4月發行的權證的終止日期延長到2029年10月12日,並對2023年的權證的“贖回權”進行了調整。公司強調投資其證券存在高度風險,並提及原招股說明書的“風險因素”部分以獲取更多詳細信息。此招股說明書的申請也已納入公司現有的S-8和F-3表格註冊聲明中。
NeuroSense Therapeutics於2024年6月27日向證券交易委員會提交了一份招股說明書,更新和修訂了其之前於2024年4月8日發佈的招股說明書。說明書涉及發行300萬普通股和權證,其可購買額外的300萬普通股。公司的普通股和權證分別在納斯達克上交易,代碼分別爲“NRSN”和“NRSNW”。2024年6月26日,普通股的收盤價爲0.85美元,權證的收盤價爲0.18美元。說明書包括來自公司提交的6-K表格的信息,該表格詳細說明了對某一名機構投資者發行的某些權證的修訂。這些修訂將於2023年6月和2024年4月發行的權證的終止日期延長到2029年10月12日,並對2023年的權證的“贖回權”進行了調整。公司強調投資其證券存在高度風險,並提及原招股說明書的“風險因素”部分以獲取更多詳細信息。此招股說明書的申請也已納入公司現有的S-8和F-3表格註冊聲明中。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息